MX9802067A - Derivados de la 2-quinolona inhibidores de la farnesil transferasa. - Google Patents
Derivados de la 2-quinolona inhibidores de la farnesil transferasa.Info
- Publication number
- MX9802067A MX9802067A MX9802067A MX9802067A MX9802067A MX 9802067 A MX9802067 A MX 9802067A MX 9802067 A MX9802067 A MX 9802067A MX 9802067 A MX9802067 A MX 9802067A MX 9802067 A MX9802067 A MX 9802067A
- Authority
- MX
- Mexico
- Prior art keywords
- 6alkyl
- 6alkyloxy
- hydrogen
- aminoc1
- ar2c1
- Prior art date
Links
- 102000007317 Farnesyltranstransferase Human genes 0.000 title abstract 2
- 108010007508 Farnesyltranstransferase Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 150000002431 hydrogen Chemical group 0.000 abstract 6
- -1 C1-6alkyloxycarbonyl Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 125000004951 trihalomethoxy group Chemical group 0.000 abstract 1
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion se refiere a compuestos de la formula (I) (Ver Formula), las formas estereoisoméricas de los mismos y las sales de adicion de ácido o base farmacéuticamente aceptable de los mismos, en los cuales la línea de puntos representa un enlace optativo; x es oxígeno o azufre; R1 es hidrogeno, alquilo C1-&, Ar1, Ar2C1-6alquilo, quinolinilC1-6aqluilo, piridilC1-6alquilo, hidroxiC1-6alquilo, C1-6alquiloxiC1-6alquilo, mono- o di(C1-6alquilo)aminoC1-6alquilo, amonoC1-6alquilo, o un radical de la formula -A1k1-C(=0)- R9 o A1k1-S(O)2-R9; R9 y R1 y R3, independientemente, son hidrogeno, hidroxi, halo, ciano, halo, ciano, C1-6alquilo, C1-6alquiloxi, hidroxiC1-6alquiloxi, C1-6alquiloxiC1-6alquiloxi, aminoC1-6alquiloxi, mono- o di(C1-6alquilo)aminoC1-6alquiloxi, Ar1, Ar2C1-6alquilo, Ar2oxi, Ar2C1-6aqluiloxi, hidroxicarbonilo, C1-6alquiloxicarbonilo, trihalometilo, trihalometoxi, C2-6alquenilo; o cuando están en posiciones adyacentes, R2 y R3 juntos pueden formar un radical bivalente; cada uno de R4 y R5, independientemente, es hidrogeno, C1-6alquilo, C1-6alquiloxiC1-6alquilo, C1-6alquiloxi, C1-6alquitio, amino, hidroxicarbonilo, C1-6alquiloxicarbonilo, C1-6alquilS(O)C1-6alquilo o C1-6alquilos(O)(2(c1-alquilo; cada uno de R6 y R7; independientemente, es hidrogeno, halo, ciano, C1-6alquilo, C1-6alquiloxi o Ar2ox1; R8 es hidrogeno, C1-6alquilo, ciano, hidroxicarbonilo, C1-6alquiloxicarbonilo, C1-6alquilcarboniloC1-6alquilo, cianoC1-6alquilo, C1-6alquiloxicarbonil C1-6alquilo, hidroxicarbonilC1-6alquilo, hidroxiC1-6aqluilo, aminoC1-6alquilo, mono- o di(C1-6alquil)-aminoC1-6alquilo, haloC1-6alquilo, C1-6aqluiloxiC1-6alquilo, aminocarboniloC1-6alquilo, Ar1C1-6alquiloxiC1-6alquilo, C1-6alquiltioC1-6alquilo; R10 es hidrogeno, C1-6alquilo; C1-6alquiloxi o halo; R11 es hidrogeno o C1-6alquilo; que tienen actividad inhibidora de la farnesiltransfereasa; su preparacion las composiciones que los contienen y su uso como medicamento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95202945 | 1995-10-31 | ||
| EP95202945.2 | 1995-10-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX9802067A true MX9802067A (es) | 1998-08-30 |
| MXPA98002067A MXPA98002067A (es) | 1998-11-12 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW349948B (en) | Farnesyl transferase inhibiting 2-quinolone derivatives | |
| HK1024689A1 (en) | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with n- or c-linked imidazoles | |
| MY114444A (en) | Farnesyl protein transferase inhibiting (imidazol-5-yl) methyl -2-quinolone derivatives | |
| BG105631A (en) | 1,2-annelated quinoline derivatives | |
| PL336468A1 (en) | Farnesil transferase inhibiting quinazolynones | |
| CA2290992A1 (en) | (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation | |
| UY25679A1 (es) | Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer | |
| AP2001002079A0 (en) | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents. | |
| MX9602837A (es) | Composiciones cosmeticas o farmaceuticas que contienen mangiferina o sus derivados. | |
| NZ528676A (en) | Use of bisphosphonates in the treatment of bone metastases associated with prostate cancer | |
| HK1003708A1 (en) | Peripheral vasodilating agent containing n-acylated 4-amino piperidine derivatives as active ingredients | |
| GB9914486D0 (en) | Medicaments | |
| DK0750618T3 (da) | Oxazolidinonderivater og farmaceutiske præparater indeholdende dem | |
| ES8802151A1 (es) | Un procedimiento para la preparacion de nuevos piridazinaminas. | |
| NO944930L (no) | Hemming av dysfunksjonell uterin blödning | |
| DK0526313T3 (da) | Nye ureaderivater, deres fremstilling og terapeutiske anvendelse | |
| MY125562A (en) | Hexahydro-pyrido (4,3-b) indole derivatives as antipsychotic drugs | |
| BR0006299A (pt) | Derivados da 4-oxo-2-ureìdo-1,4,5,6-tetra-hidro-pirimidina | |
| CY2465B1 (en) | Use of allylamine derivatives such as terbinafine,in the manufacture of a medicament for the treatm ent of helicobacter pylori infection of associateddiseases. | |
| FR2708604A1 (fr) | Utilisation de dérivés de benzènesulfonyl-indole pour la préparation de médicaments. | |
| TW329388B (en) | Intraocular irrigating solution | |
| TW358809B (en) | Phenylamidinothiophene compound and anti-inflammatory agent containing the same | |
| ES8404343A1 (es) | Un procedimiento para la prepracion de nuevos derivados de 1,4-diaminociclitol. | |
| MX9700775A (es) | Derivados de tetrahidroisoquinolina. |